- Home
- TNXP vs XIN Comparison
TNXP vs XIN Comparison
Compare TNXP & XIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- XIN
- Stock Information
- Founded
- TNXP 2007
- XIN 1997
- Country
- TNXP United States
- XIN China
- Employees
- TNXP N/A
- XIN N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- XIN Homebuilding
- Sector
- TNXP Health Care
- XIN Consumer Discretionary
- Exchange
- TNXP Nasdaq
- XIN Nasdaq
- Market Cap
- TNXP 15.1M
- XIN 15.7M
- IPO Year
- TNXP N/A
- XIN N/A
- Fundamental
- Price
- TNXP $0.15
- XIN $4.29
- Analyst Decision
- TNXP Strong Buy
- XIN
- Analyst Count
- TNXP 2
- XIN 0
- Target Price
- TNXP $53.50
- XIN N/A
- AVG Volume (30 Days)
- TNXP 25.4M
- XIN 363.9K
- Earning Date
- TNXP 11-07-2024
- XIN 01-01-0001
- Dividend Yield
- TNXP N/A
- XIN N/A
- EPS Growth
- TNXP N/A
- XIN N/A
- EPS
- TNXP N/A
- XIN N/A
- Revenue
- TNXP $12,458,000.00
- XIN $667,143,185.00
- Revenue This Year
- TNXP $62.53
- XIN N/A
- Revenue Next Year
- TNXP $26.17
- XIN N/A
- P/E Ratio
- TNXP N/A
- XIN $0.49
- Revenue Growth
- TNXP N/A
- XIN N/A
- 52 Week Low
- TNXP $0.12
- XIN $1.92
- 52 Week High
- TNXP $22.08
- XIN $7.05
- Technical
- Relative Strength Index (RSI)
- TNXP 35.86
- XIN 55.13
- Support Level
- TNXP $0.13
- XIN $3.61
- Resistance Level
- TNXP $0.18
- XIN $4.31
- Average True Range (ATR)
- TNXP 0.02
- XIN 0.78
- MACD
- TNXP 0.01
- XIN -0.05
- Stochastic Oscillator
- TNXP 30.67
- XIN 35.21
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About XIN Xinyuan Real Estate Co Ltd
Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.